## Clinical Context This is a case of **β-thalassemia intermedia** with: - Transfusion-independent anemia (Hb 8.5 g/dL) - Elevated ferritin (1200 ng/mL) from **ineffective erythropoiesis** and **extramedullary hematopoiesis**—not transfusion-related iron overload - Severe osteoporosis with vertebral fractures - Vitamin D deficiency (18 ng/mL) - Growth retardation (endocrine dysfunction) ## Pathophysiology of Bone Disease in Thalassemia Intermedia **Key Point:** Bone disease in thalassemia intermedia is **multifactorial**: | Mechanism | Contribution | |-----------|---------------| | **Iron overload** | Suppresses osteoblast function, promotes osteoclast activity | | **Ineffective erythropoiesis** | Marrow expansion → mechanical stress → trabecular loss | | **Extramedullary hematopoiesis** | Splenomegaly, hepatomegaly; further iron deposition | | **Vitamin D deficiency** | Impaired calcium absorption, secondary hyperparathyroidism | | **Hypogonadism** | Growth hormone/sex hormone deficiency from iron deposition | | **Chronic hemolysis** | Increased bone turnover | ## Management Approach **High-Yield:** Thalassemia intermedia bone disease requires **dual therapy**: 1. **Iron chelation** (reduce iron-mediated osteoblast suppression) 2. **Vitamin D/calcium supplementation** (correct metabolic deficiency) ### Why Deferasirox? - **Oral agent:** Better compliance in adolescents - **Organ-protective:** Cardiac and hepatic iron removal - **Bone-specific:** Improves osteoblast function and bone mineral density - **Dose:** 20–30 mg/kg/day (adjusted for ferritin) ### Why Vitamin D Supplementation? - Serum 25-OH vitamin D <20 ng/mL is **deficient** - Supplementation: **Cholecalciferol 1000–2000 IU daily** or **ergocalciferol 50,000 IU weekly** - Target: 25-OH vitamin D >30 ng/mL - Improves calcium absorption, reduces secondary hyperparathyroidism, promotes osteoblast differentiation ## Why NOT Bisphosphonates First? **Clinical Pearl:** Bisphosphonates (alendronate, zoledronic acid) are **second-line** in thalassemia bone disease. They: - Do NOT address the underlying iron overload or vitamin D deficiency - May impair bone remodeling if used without correcting metabolic defects - Are reserved for **persistent osteoporosis despite iron chelation and vitamin D repletion** Starting bisphosphonates without addressing iron and vitamin D is treating the symptom, not the disease. ## Monitoring After Initiation - Ferritin level (monthly initially, then 3-monthly) - Serum creatinine (deferasirox can cause renal dysfunction) - 25-OH vitamin D (recheck at 8–12 weeks) - Bone mineral density (DEXA scan at baseline and 1–2 years) - Endocrine assessment (LH/FSH, testosterone, growth hormone) [cite:Robbins 10e Ch 14]
Sign up free to access AI-powered MCQ practice with detailed explanations and adaptive learning.